TY - JOUR
T1 - Clinical efficacy of alectinib in patients with ALK-rearranged non-small cell lung cancer after ceritinib failure
AU - Oya, Yuko
AU - Yoshida, Tatsuya
AU - Kuroda, Hiroaki
AU - Shimizu, Junichi
AU - Horio, Yoshitsugu
AU - Sakao, Yukinori
AU - Hida, Toyoaki
AU - Yatabe, Yasushi
PY - 2017/11
Y1 - 2017/11
N2 - Several second-generation inhibitors of anaplastic lymphoma kinase (ALK) have demonstrated potent activity in ALK rearrangement-positive non-small cell lung cancer (NSCLC). Two of these agents, ceritinib, and alectinib, recently received approval for the treatment of ALK-rearranged NSCLC in Japan. The efficacy of treatment with a second-generation ALK inhibitor after failure with a different second-generation ALK inhibitor remains unclear. We present a series of eight patients with ALK-rearranged NSCLC treated with alectinib who experienced disease progression after ceritinib. Both crizotinib and ceritinib were administered to six patients, with four (29%) patients receiving crizotinib followed by ceritinib. Among the eight study patients, two (25%) had partial response, one (12%) stable disease, and five (63%) had progressive disease. The median progression-free survival was 3.6 months (95% confidence interval=0-7.1 months). The results of this study suggest that the second-generation ALK inhibitor alectinib has limited efficacy after initial treatment with the second-generation ALK inhibitor ceritinib.
AB - Several second-generation inhibitors of anaplastic lymphoma kinase (ALK) have demonstrated potent activity in ALK rearrangement-positive non-small cell lung cancer (NSCLC). Two of these agents, ceritinib, and alectinib, recently received approval for the treatment of ALK-rearranged NSCLC in Japan. The efficacy of treatment with a second-generation ALK inhibitor after failure with a different second-generation ALK inhibitor remains unclear. We present a series of eight patients with ALK-rearranged NSCLC treated with alectinib who experienced disease progression after ceritinib. Both crizotinib and ceritinib were administered to six patients, with four (29%) patients receiving crizotinib followed by ceritinib. Among the eight study patients, two (25%) had partial response, one (12%) stable disease, and five (63%) had progressive disease. The median progression-free survival was 3.6 months (95% confidence interval=0-7.1 months). The results of this study suggest that the second-generation ALK inhibitor alectinib has limited efficacy after initial treatment with the second-generation ALK inhibitor ceritinib.
UR - http://www.scopus.com/inward/record.url?scp=85032144757&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85032144757&partnerID=8YFLogxK
U2 - 10.21873/anticanres.12103
DO - 10.21873/anticanres.12103
M3 - Article
C2 - 29061835
AN - SCOPUS:85032144757
SN - 0250-7005
VL - 37
SP - 6477
EP - 6480
JO - Anticancer research
JF - Anticancer research
IS - 11
ER -